Performance in Initiating Qtr 3 2017-18

Id	TrustId	SubmissionId	MetaSubmissionId	Research Ethics Committee Reference Number	Integrated Research Application System Number	Submission Type	Name of Trial	First Patient Recruited?	Date of First Patient Recruited	Duration between Date Site Selected and Date Site Confirmed	Duration between Date Site Confirmed and First Patient Recruited	Duration between Date Site Selected and First Patient Recruited	Benchmark Met	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Non-Confirmation Status	Date Site Ready To Start	A - Permissions delayed/denied	B - Suspended by sponsor	C - Closed by sponsor	D - Sponsor Delays	E - Staff availability issues	F - No patients seen	G - No patients consented	H - Contracting delays	I - Rare diseases	J - Other	Comments	Reasons for delay correspond to:
114766	1078	6816	51	17/NW/0019	212375	HRA Approval	A PHASE 3B/4 RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED STUDY OF METHOTREXATE (MTX) WITHDRAWAL IN SUBJECTS WITH RHEUMATOID ARTHRITIS (RA) TREATED WITH TOFACITINIB 11MG MODIFIED RELEASE (MR) FORMULATION	Yes	03/08/2017	81	55	136	No	28/07/2016	20/03/2017	03/04/2017	10/05/2017	09/06/2017	Please Select...	07/07/2017	Y	0	0	Y	0	Y	0	0	0	0	Pfizer will take a further 3 weeks to finalise set up after CTA executed, and then set up SIV date.	Sponsor
114767	1078	6816	51	17/EE/0079	220827	HRA Approval	CL01D_168 - Avacopan in patients with Vasculitis (ANCA associated vasculitis	No		155	0	0	No	02/12/2017	25/01/2017	06/04/2017	13/06/2017	29/06/2017	Please Select...	01/09/2017	0	0	0	0	Y	0	0	0	Y	0	PI on annual leave until end of Aug 2017	NHS Provider
114768	1078	6816	51	16/SC/0655	212212	HRA Approval	KReBS: Knee Replacement Bandaging Study	Yes	27/04/2017	7	28	35	Yes	30/11/2016	23/03/2017	08/02/2017	30/03/2017	30/03/2017	Please Select...	24/04/2017	0	0	0	0	Y	0	0	0	0	0	NHS Provider
114769	1078	6816	51	17/EM/0005	215706	HRA Approval	GALACTIC-HF: A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of Omecamtiv Mecarbil on Mortality and Morbidity in Subjects With Chronic Heart Failure With Reduced Ejection Fraction	Yes	11/04/2017	19	36	55	Yes	24/10/2016	15/02/2017	15/02/2017	28/02/2017	06/03/2017	Please Select...	29/03/2017	0	0	0	0	0	0	0	0	0	Y	Issues with IT information governance delayed delivery of study IT de	NHS Provider
114770	1078	6816	51	17/SC/0142	215503	HRA Approval	The 65 Trial: Evaluating the clinical and cost-effectiveness of permissive hypotension in critically ill patients aged 65 years or over with vasodilatory hypotension	Yes	13/07/2017	104	10	114	No	22/02/2017	21/03/2017	24/04/2017	13/06/2017	03/07/2017	Please Select...	04/07/2017	0	0	0	Y	Y	0	0	0	0	0	Sponsor green light not given until 3 weeks after SIV. Research Nurse capacity issue at site also added to delay	Both
114771	1078	6816	51	16/LO/2067	209688	HRA Approval	OPTIMISE II: Optimisation of Peri-operative Cardiovascular Management to Improve Surgical Outcome II (OPTIMISE II) Trial: Open, multi-centre, randomised controlled trial of cardiac output-guided fluid therapy with low dose inotrope infusion compared to usual care in patients undergoing major elective gastrointestinal surgery.	Yes	28/11/2017	230	56	286	No	12/10/2016	15/02/2017	06/01/2017	03/10/2017	03/10/2017	Please Select...	04/10/2017	0	0	0	Y	0	0	0	0	0	0	Trial centre is starting off sites in waves; likely to initiate late July/Aug 2017 - pending SIV date	Sponsor
114772	1078	6816	51	16/LO/0436	162098	HRA Approval	APRICOT: Treatment of pustular psoriasis with the IL-1 receptor antagonist anakinra: a randomised, placebo controlled trial and associated mechanistic studies.	Yes	12/10/2017	104	64	168	No	20/01/2017	27/04/2017	05/07/2016	07/08/2017	09/08/2017	Please Select...	29/08/2017	0	0	0	Y	0	0	0	0	0	Y	unable to commence recruitment following R&D confirmation email due to pharmacy not giving green light until 22/08/2017 then sponsor green light on 29/08/2017. Recruitment delay due to no suitable patients seen within 30 day	Both
114773	1078	6816	51	16/LO/2190	201357	HRA Approval	PLUM: Pustular psoriasis, eLucidating Underlying Mechanisms	Yes	28/09/2017	104	50	154	No	03/04/2017	27/04/2017	07/03/2017	09/08/2017	09/08/2017	Please Select...	11/08/2017	0	0	0	Y	0	0	0	0	0	0	Costs agreed 04.08.17 and CTA/SoA agreed 09.08.17	Sponsor
114774	1078	6816	51	16/EM/0384	182787	HRA Approval	BMS AUGUSTUS: An Open-label, 2 x 2 Factorial, Randomized Controlled, Clinical Trial to Evaluate the Safety of Apixaban vs. Vitamin K Antagonist and Aspirin vs. Aspirin Placebo in Patients with Atrial Fibrillation and Acute Coronary Syndrome or Percutaneous Coronary Intervention	No	00/01/1900	139	0	0	No	13/06/2017	16/06/2017	21/11/2016	11/10/2017	02/11/2017	Please Select...	06/11/2017	0	0	0	0	0	Y	0	0	0	Y	SIV booked for Nov 2017. Pharmacy capacity to take onthe study caused delays	NHS Provider
114775	1078	6816	51	16/EM/0194	194984	HRA Approval	MiAA DERM 5311 Effectiveness of an image analysing algorithm to diagnose melanoma compared to gold standard histological determination	Yes	17/10/2017	44	26	70	Yes	10/07/2017	08/08/2017	24/06/2016	30/08/2017	21/09/2017	Please Select...	21/09/2017	Y	0	0	0	0	0	0	0	0	0	HRA confirmation of site added recieved 19.09.17	Sponsor
114776	1078	6816	51	17/YH/0055	215194	HRA Approval	MIDFUT - Multiple Interventions of Diabetic Foot Ulcer Treatment	No	23/11/2017	49	22	71	No	23/05/2017	13/09/2017	24/05/2017	11/10/2017	01/11/2017	Please Select...	01/11/2017	Y	0	0	0	Y	0	0	0	0	0	Due to site staff availability, study training took place on 30.10.17, therefore C&C issued 01.11.17	Please Select...
114777	1078	6816	51	17/LO/0794	223700	HRA Approval	RHCF A 52-week Multicenter, Randomized, Open-Label, Parallel-Group Study Evaluating the Efficacy and Safety of Ixekizumab versus Adalimumab in Patients with Psoriatic Arthritis who are Biologic Disease-Modifying Anti-Rheumatic Drug Naive	Yes	20/11/2017	48	69	117	No	27/02/2017	26/07/2017	28/07/2017	11/08/2017	12/09/2017	Please Select...	00/01/1900	0	0	0	0	0	Y	0	0	0	0	no suitable patients seen within 30 day timeframe	NHS Provider
114778	1078	6816	51	15/NW/0926	178681	HRA Approval	PARTNER Randomised, phase II/III, 3 stage trial to evaluate the safety and efficacy of the addition of olaparib to platinum-based neoadjuvant chemotherapy in breast cancer patients with TNBC and/or gBRCA	No	00/01/1900	94	0	0	No	17/12/2015	11/08/2017	11/05/2016	09/11/2017	13/11/2017	Please Select...	24/11/2017	Y	0	0	0	0	Y	0	0	0	0	DELAYS WITH HISTOPATHOLOGIST CAPACITY AT SITE. nO SUITABLE PATIENTS SEEN	NHS Provider
114779	1078	6816	51	12/NW/0766	111990	HRA Approval	PREDNOS 2 Short course daily prednisolone therapy at the time of upper respiratory tract infection in children with relapsing steroid sensitive nephrotic syndrome; the PREDNOS 2 study.	No		37	0	0	No	13/02/2017	26/09/2017	20/09/2017	11/10/2017	02/11/2017	Please Select...	06/11/2017	0	0	0	0	0	Y	0	0	0	0	0	NHS Provider
114780	1078	6816	51	17/LO/0334	214459	HRA Approval	FLO-ELA: FLuid Optimisation in Emergency LAparotomy. Open, multi-centre, randomised controlled trial of cardiac output -guided haemodynamic therapy compared to usual care in patients undergoing emergency bowel surgery.	Yes	19/09/2017	14	18	32	Yes	09/01/2017	18/08/2017	29/03/2017	21/08/2017	01/09/2017	Please Select...	13/09/2017	0	0	0	0	0	0	0	0	0	0	0	Please Select...
114781	1078	6816	51	17/LO/1313	224703	HRA Approval	PEPTIC v1.0 Proton Pump Inhibitors vs. Histamine-2 Receptor Blockers for Ulcer Prophylaxis Therapy in the Intensive Care Unit (PEPTIC) study: A cluster randomised, crossover, registry-embedded clinical trial of proton pump inhibitors vs. histamine-2 receptor blockers for ulcer prophylaxis therapy in the Intensive Care Unit	No		15	0	0	Within 70 Days	10/08/2017	04/12/2017	11/10/2017	08/12/2017	19/12/2017	Please Select...	08/01/2018	0	0	0	0	0	0	0	0	0	0	0	Please Select...
115095	1078	6816	51	14/SS/1031	159610	HRA Approval	STOPPIT-2 An open randomised trial of the Arabin pessary to prevent preterm birth in twin pregnancy, with health economics and acceptability	No		50	0	0	Within 70 Da	04/08/2017	25/10/2017	07/07/2016	23/11/2017	14/12/2017	Please Select...	08/01/2018	0	0	0	Y	0	0	0	0	0	0	To await sponsor green light - to commence recruitment 08/01/2018 due to Christmas break.	Sponsor
115109	1078	6816	51	17/LO/1147	222154	HRA Approval	ECZTRA 2 (ECZema TRAlokinumab trial no. 2) Tralokinumab monotherapy for moderate-to-severe atopic dermatitis	Yes	14/12/2017	28	0	0	No	15/11/2016	02/10/2017	10/08/2017	24/10/2017	30/10/2017	Please Select...	03/11/2017	0	0	0	Y	0	0	0	0	0	0	SIV booked for 31/08/2017 - postponed due to CRA a/l. Re-booked for 18/10/2017. Then re-arranged to 24/10/2017 - postponed due to study centre not received study documents not back from printers .	Sponsor
115114	1078	6816	51	15/EM/0551	191168	HRA Approval	IRONMAN: Effectiveness of intravenous iron treatment vs standard care in patients with heart failure and iron deficiency: a randomised, open-label multicentre trial	No		0	0	0	No	03/05/2017	12/10/2017	07/07/2016			Please Select...		0	0	0	Y	0	0	0	0	0	waiting for costs to be sent from Sponsor	Sponsor
115118	1078	6816	51	16/SS/0137	199347	HRA Approval	ATTEST 2 -Alteplase-Tenecteplase Trial Evaluation for Stroke Thrombolysis	No		0	0	0	No	23/06/2017	18/10/2017	11/01/2017			Please Select...		0	0	0	0	Y	0	0	0	0	0	Site Pharmacy capacity, set up planned for Jan 2018	NHS Provider